High biologics demand spurs need for greater contract manufacturing
Pharmaceutical Technology
APRIL 24, 2023
Biologics are costly to produce and sell, and the more recent modalities, such as cell and gene therapies, can be difficult to manufacture. There are fewer sites for cell and gene therapies and vaccines – 90 companies with 127 facilities, as per GlobalData figures.
130 
Let's personalize your content